Novelix Pharmaceuticals Limited has announced the completion of a preferential allotment of equity shares to a promoter group member, marking a significant corporate development for the pharmaceutical company. The transaction involves the allotment of 3,25,000 equity shares to Vupparapalli Pavani on 12th February 2026.

Share Allotment Details

The preferential allotment was executed in favor of Vupparapalli Pavani, who belongs to the promoter group category. The allotment details are structured as follows:

Shareholding Pattern Changes

The preferential allotment has resulted in significant changes to Pavani's shareholding pattern in the company:

Capital Structure Impact

The preferential allotment has modified the company's overall capital structure:

Regulatory Compliance

The company has fulfilled its regulatory obligations by filing the necessary disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Vupparapalli Pavani submitted her disclosure on 14th February 2026, while the company forwarded the compliance documents to BSE Limited on 17th February 2026.

The transaction was executed through preferential allotment mode, and no encumbrances such as pledges, liens, or non-disposal undertakings are associated with the allotted shares. The company's shares are listed on BSE Limited under the scrip code 536565 and scrip ID NOVELIX.

Novelix Pharmaceuticals Limited (formerly known as trimurthi Limited) has submitted revised unaudited financial results for the quarter ended December 31, 2025, to the BSE. The revision was necessitated due to typographical errors in the auditor's limited review report, with the corrected version submitted on February 14, 2026.

Financial Performance Overview

The company demonstrated robust financial performance during Q3FY26, with significant improvements across key metrics compared to the corresponding quarter of the previous year.

Quarterly and Nine-Month Performance

The company's performance showed consistent improvement on a sequential basis as well. Total income increased from ₹3,639.14 lakhs in Q2FY26 to ₹4,840.27 lakhs in Q3FY26. For the nine months ended December 31, 2025, the company reported total income of ₹10,714.52 lakhs compared to ₹987.35 lakhs in the corresponding nine-month period of the previous year.

Earnings Per Share and Capital Structure

The company's earnings per share (EPS) for continuing operations showed improvement, with basic EPS at ₹0.58 for Q3FY26 compared to ₹0.15 in Q3FY25. The paid-up equity share capital increased to ₹1,721.50 lakhs as of December 31, 2025, from ₹995.00 lakhs in the previous year.

Business Focus and Operations

Novelix Pharmaceuticals operates in a single business segment focused on pharmaceutical research, analysis, manufacturing, and trading of active pharmaceutical ingredients (bulk drugs). The company has discontinued activities in investment in shares, trading in shares, foods, and finance segments to concentrate on its core pharmaceutical operations.

Regulatory Compliance and Approval

The unaudited financial results were reviewed by CVS Balachandra Rao & Co., Chartered Accountants, and received a clean limited review report. The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 12, 2026. The board meeting commenced at 5:00 PM and concluded at 5:30 PM, with the results being made available on the company's website at https://novelixpharma.com .